Sunday 18 October 2026
Export BJDX’s income statement to Excel — free account
Bluejay Diagnostics, Inc.
BJDX Healthcare Medical Devices
Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00. In the quarter to June 2026, EPS grew 80.1% and free cash flow grew 20.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.75
0.03
−3.85%
Follow BJDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.54 | 2.61 | 4.61 | 2.68 | |
Current Ratio |
4.64 | 2.81 | 4.88 | 2.92 | |
Net Debt/EBITDA |
4.18 | 1.95 | 3.66 | 1.94 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.65 | 0.83 | 1.02 | 0.85 | |
Capex/Depreciation |
(2.83) | (0.31) | (3.56) | 0.00 | |
Interest Coverage |
— | — | (2,436.17) | (8,084.50) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.72) | (1.61) | (3.24) | (3.45) | |
Capex per Share |
(0.07) | (0.02) | (0.39) | 0.00 | |
Free Cash Flow per Share |
(0.79) | (1.63) | (3.63) | (3.45) | |
Cash per Share |
4.62 | 3.74 | 11.50 | 7.83 | |
Shareholders Equity per Share |
4.53 | 4.25 | 13.31 | 9.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.53 | 4.25 | 13.31 | 9.38 | |
Free Cash Flow |
(1.64) | (1.60) | (1.63) | (1.36) | |
Working Capital |
7.70 | 2.55 | 4.34 | 2.20 | |
Capital Expenditures |
(0.14) | (0.02) | (0.17) | — | |
Net Current Asset Value |
7.70 | 2.55 | 4.32 | 2.16 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Payables |
0.39 | 0.37 | 0.18 | 0.24 | |
Average Assets |
8.97 | 5.44 | 6.89 | 6.62 | |
Average Common Equity |
7.35 | 4.02 | 5.85 | 5.43 |
Columns are period end dates